DiaMedica Therapeutics to Report First Quarter 2022 Financial Results and Provide a Business Update May 5, 2022

Rhea-AI Summary

DiaMedica Therapeutics Inc. (Nasdaq: DMAC) will release its Q1 2022 financial results after market close on May 4, 2022. A live conference call is scheduled for May 5, 2022, at 7:00 AM CT to discuss the results and provide a business update. The company is focused on developing novel treatments for neurological disorders and kidney diseases, with its lead candidate DM199 targeting acute ischemic stroke and chronic kidney disease. This call offers investors crucial insights into the company’s financial health and strategic direction.

Positive

• Scheduled conference call for Q1 2022 results indicates transparency and communication with investors.

Negative

• None.

MINNEAPOLIS--(BUSINESS WIRE)-- DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that its first quarter 2022 financial results will be released after the markets close on Wednesday, May 4^th. DiaMedica will host a live conference call on Thursday, May 5^th at 7:00 AM Central Time to provide a business update and discuss financial results.

Conference Call details:
Date:		Thursday, May 5, 2022
Time:		7:00 AM CT / 8:00 AM ET
Web access:		https://events.q4inc.com/attendee/640421392
Dial In:		(888) 440-4368
Conference ID:		4814247

Interested parties may access the conference call by dialing in or listening to the simultaneous webcast. Listeners should log on to the website or dial in 15 minutes prior to the call. The webcast will remain available for play back on our website, under investor relations - events and presentations, following the earnings call and for 12 months thereafter. A telephonic replay of the conference call will be available until May 12, 2022, by dialing (800) 770-2030 (US Toll Free) and entering the replay passcode: 4814247.

About DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company committed to improving the lives of people suffering from serious diseases. DiaMedica’s lead candidate DM199 is the first pharmaceutically active recombinant form of the human tissue kallikrein-1 protein (KLK1), an established therapeutic modality for the treatment of acute ischemic stroke and chronic kidney disease. For more information visit our website at www.diamedica.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220428005087/en/

Scott Kellen

Chief Financial Officer

Phone: (763) 496-5118

skellen@diamedica.com

Source: DiaMedica Therapeutics Inc.

FAQ

When will DiaMedica Therapeutics Inc. release its Q1 2022 financial results?

DiaMedica Therapeutics Inc. will release its Q1 2022 financial results after market close on May 4, 2022.

What time is the DiaMedica conference call for Q1 2022 results?

The conference call for Q1 2022 results is scheduled for May 5, 2022, at 7:00 AM Central Time.

How can I access the DiaMedica conference call?

You can access the DiaMedica conference call by dialing (888) 440-4368 or by streaming online at the provided webcast link.

What is DiaMedica's lead candidate for treatment?

DiaMedica's lead candidate, DM199, is designed for the treatment of acute ischemic stroke and chronic kidney disease.